We are pleased to announce that Jennifer Che, Managing Director of Eagle IP, was a featured panelist at the annual Fordham Intellectual Property Law & Policy Conference held recently in New York City.

Widely regarded as one of the most prestigious gatherings in the IP world, the Fordham Conference brings together judges, practitioners, and policymakers from across the globe to discuss the most pressing issues in the field. Jennifer contributed her expertise to the China panel, where she engaged in a deep-dive discussion regarding the rapidly shifting intellectual property landscape in the region.

At Eagle IP, we remain committed to staying at the forefront of international IP policy. Jennifer’s participation in this high-level forum underscores our dedication to providing our clients with the most current and sophisticated counsel for their global IP portfolios.

Our Past Events

Recommended Insights

From Faces to Football Fields: How Applying AI Models to Different Application Fields Can Prove Inventive in China

21 October 2025
As AI models become versatile and adaptable across multiple contexts and industries, questions about inventive step sit at the heart of patent examination in China. The 2023 Patent Examination Guidelines (hereinafter referred to as 'the Guidelines') included several sessions dedicated to explaining how inventive step should be examined for AI-related inventions, featuring examples related to […]

A Detailed Dive into China’s New Patent Term Extension Provisions

11 December 2020
This article is a part of a larger article that highlights the newest draft implementation rules of the new Chinese Patent Law. This particular article takes a detailed dive into the patent term extension/adjustment provisions. One of the biggest and most exciting provisions in the newly amended patent law is patent term extension for delay […]

Is “Comparable” the New “Unexpected”? China’s SPC Relaxes Inventive Step Standard for Breakthrough Therapeutics

14 July 2026
How the Supreme People's Court Established a New Benchmark for Unexpected Technical Effects in a Landmark Diabetic Nephropathy Case Proving inventive step for pharmaceutical compounds, especially a second medical use, remains one of the most challenging aspects of patent prosecution in China. When the prior art discloses a compound's general therapeutic properties, how can an […]

How to Protect a Crystal Form (Polymorph) Patent in China

4 June 2025
Crystalline forms are critical to pharmaceutical patents, offering extended protection for improved stability, bioavailability, or manufacturability. However, securing such patents in China has grown increasingly difficult due to the China National Intellectual Property Administration (CNIPA)’s strict patentability criteria. Unlike the U.S. or Europe, where structural novelty or problem-solving utility may suffice, China demands quantifiable evidence of […]
Top crossarrow-right